ABIOSA PHARMA AS: årsregnskap 2024 vs 2023
Another loss-making year
approved 2025-05-06; registry 2025-05-08; journal 2025 415970
Summary
What changed
Comparing Årsregnskap 2024 with 2023 for ABIOSA PHARMA AS. Net result -2 486 NOK → -250 NOK. Equity -11.7k NOK → -11.9k NOK.
On the constructive side: operating result improved; net result improved.
Also worth watching: thin equity buffer. All figures are taken from the published annual accounts for ABIOSA PHARMA AS.
At a glance
Scorecard
Revenue
n/m
0 NOK
—
Operating result
-2 486 NOK
-250 NOK
+89.9%
Net result
-2 486 NOK
-250 NOK
+89.9%
Equity
-11.7k NOK
-11.9k NOK
-2.1%
Cash
4 693 NOK
4 443 NOK
-5.3%
Total assets
4 693 NOK
4 443 NOK
-5.3%
What improved
-
↑
Operating result improved
Operating result -2 486 NOK → -250 NOK. Calculated
-
↑
Net result improved
Net result -2 486 NOK → -250 NOK. Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is -268.3% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation